���ϲ�����

Non-ribosomal lipopeptides secured 46.03% of the peptide antibiotics market share in 2025, anchored by daptomycin and polymyxins that remain indispensable against resistant Gram-positive and Gram-negative infections. Daptomycin’s ability to evade BceAB-mediated resistance in Streptococcus pneumoniae sustains its frontline status. Polymyxin B and colistin regained importance as last-resort therapies for carbapenem-resistant organisms despite emerging MCR-gene resistance. Manufacturing advances, such as CordenPharma’s plant expansions, support supply stability for this mature segment.

Ribosomal RiPPs are projected to grow at a 13.08% CAGR, the highest among product classes. Synthetic-biology tooling has uncovered 987 new RiPP gene clusters in lichen fungi, opening fresh discovery space. Machine-learning guided evolution produced LBDA-D, which shows enhanced activity against Escherichia coli and S. aureus. Heterologous expression systems now enable scalable RiPP production, reducing historical supply constraints. As a result, the peptide antibiotics market size for ribosomal candidates is set for rapid expansion over the forecast period.

Skin infections accounted for 41.12% of the peptide antibiotics market size in 2025, supported by topical delivery formats that suit diabetic foot ulcers and post-surgical wounds. Locilex (pexiganan) illustrates focused development while dissolving microneedles to improve compliance in outpatient care. Long-acting lipoglycopeptides such as dalbavancin have broadened their reach beyond skin indications, reporting clinical success rates up to 100% in bloodstream infections. Growing diabetes prevalence and high rates of MRSA in community settings sustain demand for skin-directed therapeutics within the peptide antibiotics market.

Hospital-acquired and ventilator-associated bacterial pneumonia hold smaller baseline revenue but are slated for a 10.05% CAGR, the fastest among disease areas. AbbVie’s newly approved Emblaveo achieved a 76.4% cure rate in late-stage trials. Intensive-care infection rates remain high, with S. maltophilia doubling in incidence over two decades. The critical nature of respiratory infections ensures premium reimbursement and steady hospital uptake, and advanced inhalable or long-acting injectable peptides under development promise to deepen future penetration.

Injectables maintained a 69.72% revenue share in 2025, underscoring the necessity for rapid systemic exposure in severe infections. Vancomycin achieved appropriate use in 89.1% of cardiac-surgery cases following IDSA protocols. Cold-chain infrastructure and trained infusion staff favour hospital settings, keeping the peptide antibiotics market anchored in inpatient care. However, high production costs and lengthy infusion times present cost-containment challenges for payers.

Topical hydrogels, rising at a 12.29% CAGR, employ self-assembling peptide networks that achieve minimum inhibitory concentrations as low as 2 µM against MRSA. Hydrogel microspheres now pack high drug loads with controlled release, solving earlier capacity issues. Patient preference for non-invasive therapy and the reduced risk of systemic toxicity fuel adoption. The peptide antibiotics market, therefore, shows growing modality diversification beyond traditional intravenous regimens.

Hospital pharmacies controlled 56.94% of global sales in 2025 due to the acute nature of infections addressed and the sterility requirements of many formulations. Centralized compounding units and temperature-controlled storage preserve drug integrity, reinforcing hospital leadership. The prevalence of healthcare-associated infections, estimated to affect millions annually, keeps peptide antibiotic demand concentrated in inpatient care.

Online pharmacies, forecast at a 14.02% CAGR, benefit from telehealth expansion and the advancing feasibility of oral peptide delivery. Merck’s USD 493 million Cyprumed deal aims to transform peptides into tablets, a development that would expand outpatient channels. Retail pharmacies occupy a middle ground, dispensing oral agents and select topical products, but growth remains limited until more peptide antibiotics transition to community prescribing.

North America generated 38.12% of 2025 global revenue, the highest regional contribution. The FDA’s QIDP framework expedited approvals for cutting-edge agents such as Blujepa and Emblaveo, while BARDA committed USD 318 million in contracts to antimicrobial R&D. Private investments, including Eli Lilly’s USD 100 million AMR fund and CordenPharma’s plant expansion, reinforce supply and discovery capacity. Research hubs like McMaster University continue to pioneer AI-based discovery models, expanding the peptide antibiotics market footprint across North America.

Asia Pacific is the fastest-growing region with a projected 9.7% CAGR through 2031. AstraZeneca’s USD 2.5 billion Beijing R&D center enhances local peptide capabilities, while Chinese regulators approved Vibativ for serious infections, giving Cumberland Pharmaceuticals access to a vast market. Singapore’s institutes are advancing bacteriophage-peptide synergy programs, underscoring region-wide commitment to antimicrobial resistance. Government stewardship initiatives, coupled with capacity additions across India and South Korea, drive sustained uptake within the peptide antibiotics market.

Europe remains a pivotal contributor, supported by EMA streamlined pathways and manufacturing depth. Positive CHMP opinion for Pfizer’s aztreonam-avibactam highlights regulatory efficiency. Academic centres such as Chalmers University developed peptide hydrogels that boost oxacillin potency 64-fold, demonstrating innovation strength. Meanwhile, Middle East and Africa and South America show nascent adoption, aided by improving healthcare infrastructure and awareness campaigns focused on antimicrobial stewardship.. At the same time,the region's,,,the . At the same time,